Skip to main content

Table 1 Characteristics of NSCLC patients in the study cohort

From: Detection of E2A-PBX1 fusion transcripts in human non-small-cell lung cancer

   Total (%) E2A-PBX1 positive (%) E2A-PBX1 negative (%) P value Median overall survival (95% CI) P value
  Total 184 (100) 23 (12.5) 161 (87.5)   105.60 (55.41 ~ 155.79)  
Age       
  Mean (years) 66.9 ± 12.0 66.0 ± 11.7 67.0 ± 12.1 0.698*   
  Range (years) 25-91 39-84 25-91    
  <71 109 (100) 13 (11.9) 96 (88.1) 0.777 69.00 (43.73 ~ 94.27) 0.7069
  ≥71 75 (100) 10 (13.3) 65 (86.7)   105.60 (18.53 ~ 192.67)  
Gender     0.215   
  Male 78 (100) 7 (9.0) 71 (91.0)   64.70 (NA) 0.0889
  Female 106 (100) 16 (15.1) 90 (84.9)   105.60 (57.58 ~ 153.62)  
Race     0.606   0.1430
  Caucasian 136 (100) 17 (12.5) 119 (87.5)   81.70 (52.59 ~ 110.81)  
  Asian 27 (100) 3 (11.1) 24 (88.9)   64.70 (45.79 ~ 83.61)  
  Hispanic 7 (100) 2 (28.6) 5 (71.4)   NR  
  African-American 7 (100) 0 7 (100)   NR  
  Others 7 (100) 1 (14.3) 6 (85.7)    
Smoking     0.174   0.0868
  Smoker 127 (100) 19 (15.0) 108 (85.0)   69.00 (42.36 ~ 95.64)  
  Non-smoker 53 (100) 4 (7.5) 49 (92.5)   105.60 (35.86 ~ 175.34)  
  Unknown 4 (100) 0 4 (100)    
Pack/Year (smoker)       
  Mean 41.6 ± 23.5 46.3 ± 26.7 30.9 ± 35.9 0.623*   
  Range 1-160 5-90 1-160    
Gender × Smoking     0.097   0.0258
  Male, Smoker 59 (100) 5 (8.5) 54 (91.5) 0.7331 56.20 (27.25 ~ 85.15) 0.07491
  Male, Non-smoker 18 (100) 2 (11.1) 16 (88.9)   NR  
  Female, Smoker 68 (100) 14 (20.6) 54 (79.4) 0.0482 81.70 (41.68 ~ 121.72) 0.67142
  Female, Non-smoker 35 (100) 2 (5.7) 33 (94.3)   105.60 (35.04 ~ 176.16)  
  Unkown 4 (100) 0 4 (100)    
Histology     0.276   0.6013
  AIS 76 (100) 17 (22.4) 59 (77.6) 0.0063 105.60 (57.93 ~ 153.27) 0.12083
  Invasive adenocarcinoma 76 (100) 5 (6.6) 71 (93.4)   53.10 (NA)  
  Squamous cell carcinoma 18 (100) 0 18 (100)   NR  
  Carcinoid 6 (100) 0 6 (100)   NR  
  Large 4 (100) 1 (25.0) 3 (75.0)   NR  
  Others 4 (100) 0 4 (100)    
Tumor Size     0.026*   
  Mean 3.3 ± 1.9 4.1 ± 2.8 3.2 ± 1.7    
  Range 0.5-13.0 0.9-12.0 0.5-13.0    
Pathological TNM Classification       
pt pt1 74 (100) 9 (12.2) 65 (87.8) 0.408 105.60 (NA) 0.0915
  pt2 81 (100) 9 (11.1) 72 (88.9)   69.00 (44.22 ~ 93.78)  
  pt3 8 (100) 0 8 (100)   40.20 (26.06 ~ 54.34)  
  pt4 18 (100) 4 (22.2) 14 (77.8)   30.50 (NA)  
  Unknown 3 (100) 1 (33.3) 2 (66.6)    
pn pn0 144 (100) 18 (12.5) 126 (87.5) 0.924 105.60 (65.68 ~ 145.52) 0.0038
  pn1 19 (100) 3 (15.8) 16 (84.2)   47.80 (32.55 ~ 63.05)  
  pn2 17 (100) 2 (11.8) 15 (88.2)   45.50 (NA)  
  pn3 2 (100) 0 2 (100)   5.20 (NA)  
  Unknown 2 (100) 0 2 (100)    
pm pm0 171 (100) 20 (11.7) 151(88.3) 0.179 105.60 (55.99 ~ 155.21) 0.2605
  pm1 12 (100) 3 (25.0) 9 (75.0)   56.20 (35.26 ~ 77.14)  
Pathological Stage     0.426   0.0167
  Stage I 119 (100) 13 (10.9) 106 (89.1)   105.60 (65.47 ~ 145.73)  
  Stage II 22 (100) 2 (9.1) 20 (90.9)   NR  
  Stage III 29 (100) 5 (17.2) 24 (82.8)   33.60 (0.00 ~ 73.11)  
  Stage IV 12 (100) 3 (25.0) 9 (75.0)   56.20 (35.26 ~ 77.14)  
  Unknown 2 (100) 0 2 (100)    
Recurrence     0.435   <0.001
  Yes 63 (100) 6 (9.5) 57 (90.5)   39.30 (30.45 ~ 48.15)  
  No 103 (100) 14 (13.6) 89 (86.4)   NR  
  Unknown 18 (100) 1 (5.6) 17 (94.4)    
  1. * student t test.
  2. 1 between male smoker and male non-smoker.
  3. 2 between female smoker and female non-smoker.
  4. 3 between AIS and invasive adenocarcinoma.
  5. AIS: adenocarcinoma in situ; NR: not reached; NA: not available.